{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Acute Respiratory Distress Syndrome",
            "NStudiesAvail": 430108,
            "NStudiesFound": 56,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 56,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).\n\nParticipants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02804945"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [
                              "START"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01775774"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.",
                              "Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Wharton's jelly derived Mesenchymal stem cells.",
                              "Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.",
                              "Patients received one dose of normal saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell arm",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01902082"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [
                              "ARDS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension",
                              "Biological: normal saline"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608592"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [
                              "COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.",
                              "The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion IV of Mesenchymal Stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treated group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04416139"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants with moderate to severe acute respiratory distress syndrome (6 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: HCR040 (Phase 1)",
                              "Drug: Placebo (Phase 2)",
                              "Drug: HCR040 (Phase 2)"
                        ],
                        "ArmGroupLabel": [
                              "HCR040 (Phase 1)",
                              "Control group (Phase 2)",
                              "HCR040 (Phase 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive MSCs as in the Pilot study.",
                              "Patients receive standard of care.",
                              "Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cell",
                              "Other: Best Practice",
                              "Biological: Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Phase II Arm I (mesenchymal stem cells)",
                              "Phase II Arm II (standard of care)",
                              "Pilot study (mesenchymal stem cells)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04565665"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention Group1(n=20). Patients will receive two doses of MSCs 100\u00d710e6 (\u00b110%) intravenously plus Conventional treatment.",
                              "Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100\u00d710e6 (\u00b110%), intravenously plus two doses of EVs plus Conventional treatment",
                              "Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cell therapy protocol 1",
                              "Biological: Cell therapy protocol 2"
                        ],
                        "ArmGroupLabel": [
                              "Two MSC infusion",
                              "Two MSC infusion Plus two EVs infusion",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04366063"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hMSC-Exos low-dose group",
                              "hMSC-Exos medium-dose group",
                              "hMSC-Exos high-dose group",
                              "basic treatment+hMSC-Exos (a quarter of MTD/day)",
                              "basic treatment+hMSC-Exos (MTD/day)",
                              "basic treatment+normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: low dose hMSC-Exos",
                              "Biological: medium dose hMSC-Exos",
                              "Biological: high dose hMSC-Exos",
                              "Biological: Dosage 1of hMSC-Exos",
                              "Biological: Dosage 2 of hMSC-Exos",
                              "Biological: No hMSC-derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1: hMSC-Exos low dose",
                              "Phase 1: hMSC-Exos medium dose",
                              "Phase 1: hMSC-Exos high dose",
                              "Phase 2: hMSC-Exos dosage 1",
                              "Phase 2: hMSC-Exos dosage 2",
                              "Phase 2: control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04602104"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04909879"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords"
                        ],
                        "ArmGroupLabel": [
                              "COVID-19 patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [
                              "MSC-COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.\n\nday 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg",
                              "Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC Arm",
                              "Placebo Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04347967"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PLACEBO Normal saline 100 mL",
                              "IP (ExoFlo) 15ml dose in Normal saline 85 mL, which is approximately 1.2 trillion EVs."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EXOFLO",
                              "Drug: EXOFLO"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm 1",
                              "Treatment Arm 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: EV-Pure\u2122 and WJ-Pure\u2122",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Experimental/treatment arm",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05387278"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [
                              "EXIT-ARDS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Saline",
                              "ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)",
                              "ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Saline",
                              "Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles",
                              "Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupLabel": [
                              "Placebo Saline",
                              "10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles",
                              "15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group I disease 0-7. days,",
                              "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group II; 8-14 days of the disease. days",
                              "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group III; It will be divided into 3 groups as those applied on the 15th day and after."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cell Antigen-1, Human",
                              "Drug: Mesenchymal Stem Cell Antigen-1, Human",
                              "Drug: Mesenchymal Stem Cell Antigen-1, Human"
                        ],
                        "ArmGroupLabel": [
                              "stem cell application; Group I disease 0-7. days,",
                              "stem cell application; Group II; 8-14 days of the disease. days",
                              "stem cell application; Group III; those applied on the 15th day and after."
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05240430"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [
                              "ARDS-MSC-205"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Stem Cell Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [
                              "UCMSC-ALI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord MSCs are administrated to patients by intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02444455"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.",
                              "Other: Vehicle + Heparin along with best supportive care"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Positive PRA",
                              "Negative PRA",
                              "Positive PRA",
                              "Negative PRA",
                              "Positive",
                              "Negative",
                              "Borderline",
                              "Positive",
                              "Negative",
                              "Borderline"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT04355728"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [
                              "ARDOXSO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "First Cohort:\n\nFive patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 2 x 10^9 exosomes",
                              "Second Cohort:\n\nFive patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 4 x 10^9 exosomes.",
                              "Five patients will receive a treatment dose of 8 X 10^9 exosomes every other day for a period of 5 days, with a minimum of 24 hours between doses recorded.",
                              "Fourth Cohort:\n\nRandomized Cohort Up to 40 patients may be enrolled in this phase of the trial. For those receiving the placebo (~25%), 3 doses will be given over the 5 day period, dispensed from identical vials with physician and patient blinded. The full dose of 8 X 10^9 exosomes will be given to 75% of the patients in 3 doses over the course of 5 days, with one dose occurring every other day."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)",
                              "Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)",
                              "Drug: MSC-exosomes delivered intravenously every other day (8:8:8)",
                              "Drug: MSC-exosomes delivered intravenously every other day (8:8:8)"
                        ],
                        "ArmGroupLabel": [
                              "Escalating Dose First Cohort",
                              "Escalating Dose Second Cohort",
                              "Escalating Dose Third Cohort",
                              "Treatment Dose Fourth Cohort Randomized control ratio 1:3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04798716"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [
                              "REALIST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins",
                              "Plasma-Lyte 148 infused over 30 to 90 mins"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord derived CD362 enriched MSCs",
                              "Biological: Placebo (Plasma-Lyte 148)"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord derived CD362 enriched MSCs",
                              "Placebo (Plasma-Lyte 148) infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03042143"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04905836"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [
                              "STELLAR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02112500"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of placebo control and standard of care treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Other: Placebo control + best supportive care"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1 Low-dose Group",
                              "Phase 1 Middle-dose Group",
                              "Phase 1 High-dose Group",
                              "Phase 2a Treatment Group",
                              "Phase 2a Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04452097"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04377334"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [
                              "COVIDMES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton-Jelly mesenchymal stromal cells on D1 and D3",
                              "Placebo on D1 and D3"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment A",
                              "Treatment B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.",
                              "Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human derived umbilical cord derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs treatment",
                              "non-cell therapy"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04951882"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [
                              "EXIT-COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Normal saline 100 mL",
                              "Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.",
                              "Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intravenous normal saline",
                              "Biological: DB-001",
                              "Biological: DB-001"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "Experimental Dose 1",
                              "Experimental Dose 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [
                              "RECOVER"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.",
                              "Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.",
                              "Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.",
                              "Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)",
                              "Cohort (SARS-CoV-2): Arm 2 (Placebo)",
                              "Cohort 2 (Flu): Arm 3 (LMSCs)",
                              "Cohort 2 (Flu): Arm 4 (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [
                              "ACE_CARD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: Cohort 1 Low dose, 20M cells, 3 patients",
                              "Experimental: Cohort 2 Med dose, 100M cells, 3 patients",
                              "Experimental: Cohort 3 High dose, 200M cells, 3 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs",
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs",
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Medium dose",
                              "High dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05491681"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04903327"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Descartes 30"
                        ],
                        "ArmGroupLabel": [
                              "Descartes 30"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04524962"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)",
                              "Excipient"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04728698"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [
                              "COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.",
                              "Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group 1: (UCMSCs)",
                              "Group 2: (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04490486"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intubated without comorbidity",
                              "Intubated with comorbidity",
                              "No intubated"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cells",
                              "Other: Mesenchymal stem cells",
                              "Other: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04713878"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of remestemcel-L 2x10^6 MSC/kg of body weight plus standard of care",
                              "Placebo (Plasma-Lyte) plus standard of care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Remestemcel-L",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L Plus Standard of Care",
                              "Placebo Plus Standard of Care"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04371393"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day \"1\", Day \"4\", Day \"7\".",
                              "Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [
                              "STROMA-CoV2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord Wharton's jelly-derived human",
                              "Other: NaCl 0.9%"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "NaCl"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving regular respiratory distress treatment",
                              "Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive up to 2 infusions of mesenchymal stem cells.",
                              "Patients will receive supportive care or treatment designated by their treating doctor."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Supportive Care"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04345601"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [
                              "ULSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS:\n\nIn Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen.",
                              "Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS:\n\nIn Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability.",
                              "Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS:\n\nIn Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Lining Stem Cells (ULSC)",
                              "Biological: Umbilical Cord Lining Stem Cells (ULSC)",
                              "Other: Placebo (carrier control)"
                        ],
                        "ArmGroupLabel": [
                              "ULSC in Phase 1 Open Label",
                              "ULSC in Phase 2a Randomized",
                              "Placebo in Phase 2a Randomized"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04494386"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies",
                              "On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106/Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Oseltamivir",
                              "Drug: hormones",
                              "Device: oxygen therapy",
                              "Drug: Oseltamivir",
                              "Drug: hormones",
                              "Device: oxygen therapy",
                              "Procedure: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04371601"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [
                              "MEND"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The investigational medicinal product used in this study is known as CYP-001. The active agent in CYP-001 is Cymerus\u2122 MSCs. CYP-001 is supplied as 100 million Cymerus MSCs formulated in 20 mL cryoprotectant medium. On D1 and D3, each participant randomised to receive CYP-001 will receive an IV infusion of 2 million Cymerus MSCs/kg of body weight (up to a maximum of 200 million cells per infusion).",
                              "Control participants will be randomised to received standard of care treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CYP-001"
                        ],
                        "ArmGroupLabel": [
                              "CYP-001",
                              "Standard of care"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04537351"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment",
                              "Patients received standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis",
                              "Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis"
                        ],
                        "ArmGroupLabel": [
                              "BMSC group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02985346"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: fetal blood transfusion"
                        ],
                        "ArmGroupLabel": [
                              "standard protocol of manaegement",
                              "fetal blood"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05092724"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [
                              "CIRCA-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "25 million cells/unit dose (cumulative dose: 75 million MSCs)",
                              "50 million cells/unit dose (cumulative dose: 150 million MSCs)",
                              "up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Panel 1",
                              "Panel 2",
                              "Panel 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04400032"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [
                              "CEL&VAL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Device: Zephyr Endobronchial Valve",
                              "Biological: Marrow-derived mesenchymal stromal cell",
                              "Device: Zephyr Endobronchial Valve"
                        ],
                        "ArmGroupLabel": [
                              "Endobronchial valve + marrow-derived mesenchymal stromal cell",
                              "Endobronchial valve"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04018729"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three fixed doses of MSC approximately 48 hours apart.",
                              "Three fixed doses of placebo control approximately 48 hours apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04466098"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).\n\nMaximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ABMD-MSC"
                        ],
                        "ArmGroupLabel": [
                              "ABDM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [
                              "COVID-19EXO2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants (n=30) in this group will receive standard therapy and exosomes of the first type.",
                              "Participants (n=30) in this group will receive standard therapy and exosomes of the second type.",
                              "Participants (n=30) in this group will receive standard therapy and inhalation placebo solution."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EXO 1 inhalation",
                              "Drug: EXO 2 inhalation",
                              "Drug: Placebo inhalation"
                        ],
                        "ArmGroupLabel": [
                              "EXO-1",
                              "EXO-2",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04602442"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [
                              "COVID-19EXO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EXO 1 inhalation",
                              "Drug: EXO 2 inhalation",
                              "Drug: Placebo inhalation"
                        ],
                        "ArmGroupLabel": [
                              "EXO-1",
                              "EXO-2",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003"
                        ],
                        "NCTId": [
                              "NCT04491240"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [
                              "ASC COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100 million allogeneic adipose-derived mesenchymal stromal cell",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Stem Cell Product",
                              "Drug: Stem Cell Product"
                        ],
                        "ArmGroupLabel": [
                              "ASC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first 10 consecutive patients will all receive investigational product.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo. The investigational product will be further randomized to the MSCs manufactured by Duke or University of Miami. These products are considered to be comparable.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Open Label infusion of hCT-MSC",
                              "Randomized infusion of hCT-MSC",
                              "Randomized infusion of Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  }
            ]
      }
}